863248-28-6Relevant articles and documents
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)
Lu, Tingting,Cao, Jiangyan,Zou, Fengming,Li, Xixiang,Wang, Aoli,Wang, Wenliang,Liang, Huamin,Liu, Qingwang,Hu, Chen,Chen, Cheng,Hu, Zhenquan,Wang, Wenchao,Li, Lili,Ge, Jian,Shen, Yang,Ren, Tao,Liu, Jing,Xia, Ruixiang,Liu, Qingsong
, (2021/02/26)
As the critical driving force for chronic myeloid leukemia (CML), BCR gene fused ABL kinase has been extensively explored as a validated target of drug discovery. Although imatinib has achieved tremendous success as the first-line treatment for CML, the l
Spiro derivative, preparation method thereof and application of spiro derivative in medicine
-
, (2021/08/19)
The invention relates to a spiro derivative, a preparation method thereof and application of the spiro derivative in medicine. Specifically, the invention relates to the spiro derivative shown in a general formula (I), the preparation method thereof, a pharmaceutical composition containing the spiro derivative and application of the spiro derivative as a therapeutic agent, especially application of the spiro derivative as an RAF inhibitor and application of the spiro derivative in preparation of drugs for treating or preventing various diseases (including cancers) related to over-expression RAF activity.
Synthetic method of intermediate of flumatinib mesylate
-
Paragraph 0013; 0028-0029; 0032; 0037; 0039; 0041; 0045-0051, (2018/03/26)
The invention discloses a synthetic method of an intermediate of flumatinib mesylate, and particularly relates to a preparation method of a key intermediate for synthesizing flumatinib mesylate. The initial raw material 4-methyl-3-trifluoro-methyl methyl